ION Geophysical Corporation (NYSE:IO) belongs to Basic Materials sector. Its net profit margin is -64.00% and weekly performance is -6.72%. On last trading day company shares ended up $1.11. ION Geophysical Corporation (NYSE:IO) distance from 50-day simple moving average (SMA50) is -24.72%. ION Geophysical Corporation (NYSE:IO) announced that on July 2, 2015, a panel of justices on the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. reversed in part and affirmed in part the patent infringement judgment against ION in favor of WesternGeco granted by the United States District Court for the Southern District of Texas in May 2014.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) shares moved up 12.14% in last trading session and ended the day at $3.14. EBIO return on assets is -72.10%. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) quarterly performance is -69.31%. An investigation on behalf of current long-term investors in shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Eleven Biotherapeutics.
On 14 July, CMS Energy Corp. (NYSE:CMS) shares fell -0.18% and was closed at $33.76. CMS EPS growth in last 5 year was 16.00%. CMS Energy Corp. (NYSE:CMS) year to date (YTD) performance is -1.25%. The Board of Directors of CMS Energy Corp. (NYSE:CMS) has declared a quarterly dividend on the company’s common stock. The dividend for the common stock (CUSIP: 125896100) is 29 cents per share. It is payable August 31, 2015, to shareholders of record on August 7, 2015.
Aratana Therapeutics, Inc. (NASDAQ:PETX) ended the last trading day at $16.77. Company weekly volatility is calculated as 4.96% and price to cash ratio as 6.70. Aratana Therapeutics, Inc. (NASDAQ:PETX) showed a weekly performance of 13.08%. Aratana Therapeutics, Inc. (NASDAQ:PETX) announced positive results from its pivotal field effectiveness study of AT-003, the company’s innovative drug for treating post-surgical pain in dogs.
CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares advanced 4.08% in last trading session and ended the day at $2.81. CBAY return on assets is -67.80%. CymaBay Therapeutics Inc. (NASDAQ:CBAY) quarterly performance is -52.85%.CymaBay Therapeutics (NASDAQ: CBAY) announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. CymaBay also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallotments, if any. CymaBay anticipates using the net proceeds from the offering for general corporate purposes, including clinical trials, research and development, capital expenditures and working capital.